P50 Suppression in Individuals at Risk for Schizophrenia: The Convergence of Clinical, Familial, and Vulnerability Marker Risk Assessment
- 15 June 2005
- journal article
- research article
- Published by Elsevier in Biological Psychiatry
- Vol. 57 (12) , 1504-1509
- https://doi.org/10.1016/j.biopsych.2005.03.003
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Preattentional and attentional cognitive deficits as targets for treating schizophreniaPsychopharmacology, 2004
- Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophreniaClinical Neurophysiology, 2004
- Olanzapine Effects on Auditory Sensory Gating in SchizophreniaAmerican Journal of Psychiatry, 2003
- Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics, and the identification of the schizophrenia prodromePsychiatric Clinics of North America, 2002
- Neurobiological Measures of Schizotypal Personality Disorder: Defining an Inhibitory Endophenotype?American Journal of Psychiatry, 2002
- Quantitative neural indicators of liability to schizophrenia: Implications for molecular genetic studiesAmerican Journal of Medical Genetics, 2001
- Sensory Gating Deficits Assessed by the P50 Event-Related Potential in Subjects With Schizotypal Personality DisorderAmerican Journal of Psychiatry, 2000
- Poor P50 Suppression Among Schizophrenia Patients and Their First-Degree Biological RelativesAmerican Journal of Psychiatry, 1998
- P50 Suppression among schizophrenia and normal comparison subjects: A methodological analysisBiological Psychiatry, 1997
- The Family History Method Using Diagnostic CriteriaArchives of General Psychiatry, 1977